AVN submits expanded Neurodex NDA
More News related to AVN
- Hughes and Avanti Sign Breakthrough European Ka-Band Satellite Agreement
- Cohen's SAC Capital Accumulates Stakes in Target (TGT), Pilgrim's Pride (PPC) and Some Financials (STI, FITB, STT)
- AVANIR (AVN) Approved For Nasdaq Listing Under Symbol AVNR
- AVN submits expanded Neurodex NDA
- 01/03: StreetInsider.com Pre-Open Movers:
More News related to FDA
- Bove Says US Banking System, Dollar to Benefit from Dubai Crisis
- GLD Bounces
- Active equity option families in first 30 minutes of trading: C BAC GE AAPL
- CBOE Volatility Index-VIX up 4.03 to 24.51
- UltraShort Gold ProShares (GLL) Up As Gold Is Weaker
AVANIR Pharmaceuticals (AMEX: AVN.R) completed the submission of its new drug application (NDA) to the FDA for Neurodex, seeking marketing approval of the drug candidate for the treatment of involuntary emotional expression disorder, also known as pseudobulbar affect or emotional lability. The application was resubmitted to the FDA to provide an expansion of certain summary analyses which better support the electronic common technical document format.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
